Roundtable Participants

Five voices — spanning health policy, laboratory medicine, urology, patient advocacy, and research — convened to examine the true scope of the UTI crisis from clinical, economic, public health, and patient-centered perspectives.

Executive Summary

Urinary tract infections are among the most common infectious conditions in the United States, generating more than 13 million diagnosed cases annually and an economic burden estimated at over $6 billion per year.1,11 Much of that spending is avoidable. It is a system hindered in waste and inefficiency — retreatment cycles, clinical resource allocation, escalated care, emergency department visits, and hospitalizations that are the direct downstream consequence of getting the wrong answer at the point of the first clinical decision.

Yet despite this scale, UTIs occupy a paradoxical position in healthcare: ubiquitous and well-recognized, yet consistently treated as routine. The systemic burden they produce is underestimated. The care pathways that manage them are largely unchanged from decades-old protocols. The consequences of diagnostic and therapeutic failure — recurrence, resistance, hospitalization, sepsis, and death — are normalized as acceptable outcomes rather than recognized as the symptoms of a solvable crisis.

This white paper presents findings from a structured multi-stakeholder roundtable convened by Pathnostics, Inc. in 2026. The panel brought together a health policy expert, a clinical microbiologist and former laboratory medicine leader, a physician-scientist urologist, and two patient advocacy researchers to examine the true scope of the UTI crisis from clinical, economic, public health, and patient-centered perspectives.

The panel's central finding is consistent across all perspectives: UTI management in the United States represents a solvable systemic failure that has been normalized. The diagnostic tools most widely used today — standard urine culture, dipstick urinalysis, and conventional antibiotic susceptibility testing — are lacking. These tools perform poorly against the full spectrum of patients who present with UTI symptoms in modern clinical settings, both in what they detect and in the treatment direction they provide. The result is a cascade of downstream harms: antibiotic prescriptions that miss the pathogen or target the wrong one, treatment failures that are treated as expected rather than avoidable, recurrence patterns that go unmeasured, and a progressive acceleration of antimicrobial resistance.

The panel reached consensus around four primary imperatives for change. These are presented in detail in this document and synthesized into a Why Change framework intended to equip clinicians, health system leaders, payers, and policymakers with the evidence and language needed to act.

A synthesis of the panel's consensus.

Common, catastrophic, and consistently misunderstood.

Urinary tract infections are the most common bacterial infection seen in primary care. An estimated 13 million cases are diagnosed each year in the United States, accounting for 8 to 10 million physician office visits and more than one million emergency department visits11 annually. The lifetime incidence in women is 50–60%, with 30% of those who experience a first episode going on to develop recurrent infection defined as two or more UTIs in six months or three or more in a year.12 Across all patient populations, UTI is responsible for approximately 25% of all sepsis cases in the US,13 more than 600,000 hospitalizations,11 and more than 87,000 deaths each year14–16 — making UTI one of the top four infection-related causes of death in the United States.

The aggregate annual economic burden to the US healthcare system is estimated at over $6 billion1 — a figure that substantially understates total societal cost once lost productivity, missed work, childcare disruption, and the downstream burden of unresolved infection are included.17–20 Critically, much of this spending is avoidable: it is the direct consequence of getting the initial diagnosis and treatment wrong. More than half (53.5%) of all UTI-related Medicare costs arise from escalated care — urgent care visits, emergency department encounters, inpatient hospitalizations, and skilled nursing facility stays — all of which are downstream consequences of first-line failure.1 The physician who prescribes the wrong antibiotic rarely sees the cost of that decision. The morbidity, the mortality, and the expense show up elsewhere — in the emergency department, in the hospital, in the patient's life — disconnected from the clinical encounter that set the cascade in motion.

What is not being counted.

Beyond direct healthcare utilization, the panel identified a substantial hidden burden that is systematically absent from epidemiological estimates. This hidden burden takes three forms.

The first is the undocumented patient population. As Melissa Kramer, PhD, noted, researchers and clinicians consistently lack the ability to quantify how many patients are experiencing recurrent or chronic UTI at any given time because care pathways are fragmented and record-keeping does not capture the full longitudinal picture. Patients who abandon the healthcare system after diagnostic and treatment failures — a pattern documented in patient advocacy communities globally — simply disappear from the data.

The second is the systematic underreporting of recurrence as failure. In standard clinical practice, a first antibiotic that does not resolve infection is not categorized as a treatment failure — it is treated as a first step in a process. This framing means that the scale of first-line failure is not captured in any quality metrics, not reported to payers, and not visible to clinicians as a pattern requiring intervention. Compounding this is the fragmentation of care itself: when a patient presents to a urologist after multiple failed courses in primary care, the urologist typically restarts the same workup — culture, potential empiric antibiotic, wait — many times without visibility into what has already been tried and failed. The same inadequate tools are applied again, producing the same inadequate results, while the patient's clinical trajectory worsens.

The third is quality-of-life impact. Patient-reported outcomes research conducted by Kramer's team demonstrates that recurrent UTI affects multiple domains of quality of life, including sexual wellbeing, productivity, social functioning, and psychological health. These impacts compound with every episode and are not reflected in clinical encounter data. There was no validated patient-reported outcome measure for recurrent UTI until Kramer's team developed one — and like most patient-reported outcome instruments in emerging fields, it is not yet widely used in clinical practice. This underscores how thoroughly this dimension of burden has been absent from clinical measurement frameworks.

A condition disproportionately borne by women.

The UTI crisis disproportionately affects women. Approximately 80% of all UTIs occur in women,21 and the quality-of-life burden — including the dismissal and invalidation women frequently encounter in clinical settings — compounds the physical experience of the condition. Patient advocacy communities globally report that the most common barrier to care is not access, but dismissal: the experience of having symptoms minimized, testing treated as definitive when it is not, and the patient's own account of their condition treated as unreliable.

As Hannah Helgeson of Let's Talk UTI observed, these patterns are consistent across countries, healthcare systems, income levels, and demographics. The UTI crisis is not a problem of poverty or access alone — it is a problem of how the condition is regarded and managed across medicine.

The most actionable root cause of the UTI crisis is diagnostic. The failure is twofold: the tools most widely used to diagnose UTI fail in what they detect, and the tools used to direct treatment fail in the guidance they provide.

As Frank Cockerill, MD, framed it, the diagnostic standard must be measured on two axes: does it find everything that is clinically relevant, and does it tell you accurately what to do about it? The current standard fails on both.

The diagnostic threshold that underlies standard urine culture — the requirement that urine contain greater than 10⁵ colony-forming units per milliliter (CFU/mL) of a single organism to be considered a positive result — was derived from a single study published by Edward Kass in the 1950s.3 That study was conducted on pregnant women who were asymptomatic but at risk for pyelonephritis. Its purpose was to predict which women would progress to upper urinary tract disease, not to serve as a universal diagnostic standard for all UTI presentations across all patient populations.

As Dr. Cockerill stated: this threshold has nothing to do with the full spectrum of patients who present with urinary symptoms today. Yet it remains the operational basis for the diagnostic tool that most clinicians rely on for treatment decisions.

The consequences of this legacy are concrete. Standard urine culture (SUC) is optimized for the growth of gram-negative organisms, primarily Escherichia coli. It does not effectively detect polymicrobial infections, fastidious organisms, or gram-positive pathogens that increasingly account for UTI burden in the patient populations most commonly seen in urology and primary care. Data suggest that SUC may miss over 55% of organisms present22 and returns indeterminate results ("mixed flora") in up to 50% of specimens23–25 — a rate that should disqualify any diagnostic tool from front-line clinical use.

Why finding the pathogen is not enough.

Detection is not direction. Even when the causative organisms are correctly identified, the question that matters most to the clinician — which antibiotic will work against this patient's infection — is not reliably answered by the tools in widespread use.

Conventional antibiotic susceptibility testing (AST) evaluates organisms individually, in isolation. But UTIs are frequently polymicrobial.25 When multiple organisms are present and interacting, their combined antibiotic susceptibility profile may differ significantly from what individual-organism testing predicts.26–32 A test that reports susceptibility for each organism separately, without evaluating how those organisms behave together in the presence of an antibiotic, can lead directly to treatment failure — even when the organism identification was accurate.

PCR-only molecular testing introduces a different version of the same problem. Multiplex PCR dramatically improves detection: it identifies more organisms, including fastidious and slow-growing species that culture misses.33,34 But identification alone does not provide treatment direction. Without validated, phenotypic susceptibility data, a PCR-only result tells the clinician what is there without telling them what to do about it. The clinical consequence is predictable: more organisms detected, but no improvement — and potentially a worsening — in the accuracy of the treatment decision that follows.35

To put it concretely: if culture detects organisms in 100 patients and directs treatment incorrectly in 50 of them, and PCR detects organisms in 150 patients but still directs treatment incorrectly in half (75) of them, PCR has expanded the scope of detection while expanding the scope of wrong answers. Detection without accurate direction is not a solution. It is the same problem scaled by more sensitive technology.

What makes this worse is that some companies offering PCR-based UTI diagnostics have entered the market making claims about treatment direction — including claims about phenotypic analysis — that are not supported by peer-reviewed evidence or validated against clinical standards. These unproven claims have not only failed to advance the standard of care; they have actively hurt adoption of evidence-based approaches that do work, by creating confusion among clinicians and laboratory directors about what molecular diagnostics can and cannot deliver.

48–72 hours of clinical guesswork.

Beyond sensitivity and direction limitations, standard urine culture creates a structural window of harm through its turnaround time. Final susceptibility results typically require 48–72 hours.36–38 During this interval, the standard of care is to prescribe an antibiotic based on clinical judgment and local antibiogram patterns rather than patient-specific susceptibility data.

The clinical consequences of this window are well-documented. Approximately 30% of antibiotics prescribed for UTI during this window are subsequently found to be inappropriate when results return.39,40 In outpatient antibiotic prescribing overall, 68% of UTIs receive an antibiotic regimen that could be optimized.2 Each inappropriate course extends the patient's symptomatic period, exposes the patient to side effects without therapeutic benefit, creates selective pressure for resistant organisms, generates additional healthcare utilization — and is typically not classified as a failure but as a normal step in the management process.

Dipstick urinalysis, the most widely used initial screening tool for UTI, presents a distinct but related problem.

The dipstick tests for leukocyte esterase and nitrites — markers that are primarily sensitive to E. coli and other gram-negative organisms. Its sensitivity and specificity for detecting true UTI is limited,41 and it provides no information about the specific pathogen, its antibiotic susceptibility, or the presence of polymicrobial infection. Together with standard urine culture, it creates a diagnostic approach that is simultaneously slow, insensitive, non-specific for treatment direction, and not designed for the patient populations most at risk of treatment failure.

The panel also identified the 'complicated versus uncomplicated UTI' distinction as an underappreciated contributor to diagnostic failure. Dr. Cockerill noted that the clinical meaning of these terms is contested, poorly defined, and inconsistently applied across clinical settings. The European Association of Urology has moved to abandon the terminology altogether; other major guidelines are in the process of revision. The result is significant unexplained clinical variation in how patients are classified, what testing is ordered, and what treatment is prescribed — even within the same institution.

The Treatment Failure Cascade.

Diagnostic limitations produce treatment failure. Treatment failure, in the UTI context, is not a discrete event with a clear clinical flag — it is a cascade of downstream consequences that accumulates over time and across multiple clinical encounters, many of which are never connected back to the original diagnostic gap.

Treatment failure in UTI occurs in up to 20% of uncomplicated cases and in more than one in five recurrent or complicated UTI cases.39,40 When treatment fails, the patient returns — or does not. Either outcome is problematic. Patients who return for retreatment generate additional healthcare utilization, additional antibiotic exposure, and additional opportunity for resistance selection. Patients who do not return are frequently assumed to have resolved, when in fact they may have sought care elsewhere, abandoned the healthcare system, or resigned themselves to living with a condition they believe is unresolvable.

The panel noted that the clinical framing of UTI management actively conceals the scale of failure. As Dr. David Nash observed, a first antibiotic that does not work is not called a treatment failure in UTI — it is called the first step in the process. This linguistic normalization of failure removes the feedback signal that would, in other clinical contexts, trigger review and practice change.

For patients with recurrent UTI, the consequences of repeated diagnostic and treatment failure compound over time in two critical ways. First, each antibiotic course that does not resolve infection increases the probability that subsequent infections will involve organisms with acquired resistance.42 Dr. Glenn Werneburg's clinical experience with neurogenic bladder patients — who receive antibiotics for multiple indications over years of care — illustrates the endpoint of this trajectory: patients for whom there are no remaining good antibiotic options.

Second, the pattern of recurrence itself is not routinely tracked or measured in most clinical settings. There is no widely used follow-up protocol that asks whether symptoms resolved, no standard metric for time to symptom improvement, and no systematic capture of recurrence intervals. The individual clinician who sees a patient for a third or fourth UTI episode may not know whether the prior episodes were truly resolved or merely suppressed, whether the same organism is responsible, or whether the antibiotic choices made previously have been contributing to the patient's current presentation.

The downstream clinical trajectory from undertreated or misdirected UTI is well-characterized in the literature, even if it is poorly visible in outpatient practice metrics. When an uncomplicated UTI is treated with an ineffective antibiotic, the patient is more than twice as likely to experience a repeat office visit, progress to complicated UTI including pyelonephritis or bacteremia, or require hospitalization within 28 days.39

At the population level, UTI drives approximately 25% of all sepsis cases in the United States13 — making it one of the most common infectious drivers of a condition that generates enormous ICU utilization, mortality, and long-term disability.

Globally, E. coli, the most common UTI pathogen, accounts for 25% of all antimicrobial resistance-related deaths; fluoroquinolone-resistant E. coli alone caused more than 50,000 global deaths in 2019.43

Perhaps the most clinically and commercially significant finding of the panel is the phenomenon of patient abandonment. Dr. Melissa Kramer's research, encompassing survey data from approximately 100,000 patients and hundreds of individual interviews, documents a consistent pattern: once a test has failed and a treatment has failed, patients are less likely to seek further diagnosis or treatment. They cycle through providers, encounter dismissal, and eventually either leave the healthcare system or accept chronic suffering as their baseline.

This invisible cohort — patients who have given up on receiving effective UTI care — represents both a profound patient welfare failure and a significant unmet need. Organizations like Live UTI Free and Let's Talk UTI attract up to one million English-language visitors annually seeking information that the healthcare system has not provided them. This is not a small niche population. It is the unmeasured majority of patients in whom the current standard of care has produced no lasting resolution.

Systemic & structural barriers to change.

The clinical and scientific case for improving UTI diagnostics is not new. The limitations of standard urine culture have been documented in the peer-reviewed literature for more than a decade.44 Advanced molecular diagnostic tools exist and have been validated. And yet practice patterns in UTI management have remained largely static. The panel examined why this is the case.

Dr. David Nash offered perhaps the most direct diagnosis of the systemic barrier: physician workflow is not simply a habit — it is a deeply embedded organizational artifact, shaped by mentorship, institutional culture, and payment structures that can persist for decades in the absence of active intervention.

This observation is supported by data. Dr. Nash cited evidence that error rates in ambulatory care settings are four times higher than in inpatient settings — a counterintuitive finding that reflects the lack of systematic feedback, quality oversight, and performance measurement in the outpatient environment where most UTIs are managed. In a system where first-line failure is not recorded as failure, there is no quality signal to drive change.

Dr. Frank Cockerill identified a parallel barrier in the clinical laboratory. Laboratory directors and microbiologists operate within their own workflow constraints and professional norms, and UTI diagnostics occupy a low-prestige position relative to other areas of laboratory medicine. The operational reality of high-volume urine processing in large commercial laboratories — tens of thousands of specimens daily, optimized for throughput — creates institutional resistance to any change that would require retraining, process redesign, or new reimbursement pathways.

This inertia has been compounded rather than relieved by the entry of PCR-only diagnostic companies into the UTI space. Companies that have made claims about treatment direction without validated phenotypic evidence have created a credibility problem for the entire category of advanced UTI diagnostics. Clinicians and laboratory directors who adopted these tools and did not see the promised improvement in clinical outcomes have become more skeptical of all molecular approaches — including those that do have the evidence to support their claims. The false promise of PCR alone has not merely failed to advance adoption; it has actively hindered it.

Dr. Cockerill identified four variables that must be addressed simultaneously for any new diagnostic to achieve laboratory adoption: accuracy, turnaround time, workforce requirements (FTE impact), and reimbursement clarity. A new test that addresses three of the four will typically fail to achieve scale.

Dr. Nash's observation that the organizational setting and how a clinician is paid greatly influences their clinical decision-making identifies the deepest structural barrier. Clinicians in fee-for-service environments have limited incentive to invest time in diagnostic uncertainty when empiric treatment is reimbursed and retreatment generates another billable encounter. Clinicians in capitated or value-based care environments, by contrast, have direct economic incentive to achieve first-pass resolution and reduce downstream utilization, however, this is often juxtaposed against workflow practices as outlined above.

This means that the Why Change message is not uniform across clinical settings. The economic argument for better UTI diagnostics is most immediately compelling in environments where the clinician or system bears financial responsibility for downstream outcomes — and least compelling where the cost of failure is distributed across payers and across the patient's subsequent encounters in different settings.

Dr. Melissa Kramer cited the well-documented average of 17 years between scientific discovery and implementation in clinical practice as a structural challenge to diagnostic innovation in UTI.45,46 The evidence base supporting advanced molecular diagnostics with antibiotic susceptibility testing is accumulating rapidly, but the pathway from peer-reviewed publication to guideline revision to practice change is slow. Clinical practice does not change until guidelines change, and guidelines do not change without repeated, independently validated evidence.

Dr. Kramer's research highlights a final structural barrier that operates at the level of the individual clinical encounter: the near-total absence of shared decision-making in UTI management. Patients who have researched their condition, who have experienced multiple treatment failures, and who are willing to pay out-of-pocket for more advanced testing are routinely told by clinicians that such testing is not appropriate for them. The systemic gender bias that characterizes UTI care means that patients' accounts of their own experience are frequently discounted relative to a diagnostic result that may itself be inaccurate.

The panel was convened with an explicit goal: to develop a credible, multi-stakeholder 'Why Change' narrative that can shift the perception of UTI management from 'this is how we have always done it' to 'this is a solvable systemic failure.' What follows is a synthesis of the panel's collective voice into four Why Change arguments — each grounded in the roundtable discussion, each calibrated for a specific clinical or administrative audience, and each designed to be actionable.

The clinical Why Change is straightforward: a diagnostic approach that delivers pathogen identification and accurate antibiotic effectiveness data within 24–36 hours enables targeted therapy from the first treatment decision. Getting it right the first time is not just a quality imperative — it is the most efficient clinical pathway available. Every retreatment is a patient who stayed sick longer than necessary.

The panel also emphasized a critical point about front-line diagnostic strategy. For specific patient populations — the elderly, patients with diabetes, men, patients with neurogenic bladder, patients with recurrent UTI, and other high-risk groups — clinicians need to rethink what constitutes a front-line diagnostic tool. The standard should not be culture first, always. When a patient arrives in urology after multiple failed courses in primary care, restarting the same workup with the same tools that already failed is not a diagnostic strategy — it is the repetition of a known failure. Modern, evidence-supported tools should be the front-line approach for populations where culture has already demonstrated its inadequacy.

Effective management means not just treating the current infection, but preventing the next one. As Dr. Werneburg noted, preventing UTIs is as important as treating them, and doing so requires understanding the patient's specific infection ecology — information that standard culture cannot reliably provide.

Dr. Frank Cockerill framed the economic argument precisely: if you have accuracy in the beginning and give the right antibiotic, you reduce follow-up visits for continuing symptoms or recurrence. Economic analyses demonstrating this reduction are what will get the attention of CFOs and laboratory directors who otherwise resist the cost of a more advanced test.

Each ineffective antibiotic course for uncomplicated UTI in adult women generates $570–$1,013 in direct medical expenses.47 Treatment failure drives escalation to more expensive care settings. More than half of UTI-related Medicare costs come from escalated care that follows primary treatment failure.48 The test that prevents the second visit pays for itself — and the opportunity cost of not using it is measured not only in dollars but in the clinical time and attention diverted from higher-value work.

Dr. David Nash identified the payment environment as the key variable: the organizational setting and how a clinician is paid greatly influences their clinical decision-making. In value-based care contracts, bundled payment arrangements, and capitated environments, the economic case for first-pass diagnostic accuracy is direct and immediate. In fee-for-service environments, the argument must be made on practice efficiency — the time and staff resources consumed by UTI retreatment that could be directed to higher-value clinical work.

The patient Why Change argument is anchored in a single, powerful observation: there was no validated patient-reported outcome measure for recurrent UTI until Dr. Kramer's team developed and published one. This is not a gap at the edges of measurement — it is the absence of any systematic effort to ask patients whether their treatment worked, whether their symptoms resolved, and whether their quality of life improved. It reflects a healthcare process that has lost sight of its most important stakeholder. The patient experience has been entirely external to the clinical feedback loop.

The practical implication is that incorporating patient-reported outcomes into UTI management — even a simple follow-up question at two weeks — would generate the feedback signal needed to identify failure patterns, trigger review, and drive the practice change that quality metrics alone have not produced.

Kramer and Helgeson also identified a structural patient advocacy demand: patients who have done their own research, who understand their options, and who are willing to seek better care deserve shared decision-making — a genuine conversation about what testing is available, what it reveals, and what it makes possible. For a condition where most patients are women and where systemic gender bias has historically minimized both their symptoms and their agency, this is not a secondary consideration.

The antimicrobial resistance dimension of this problem is both urgent and underweighted in current policy discussions. As Dr. Werneburg observed, each inappropriate antibiotic course selects for resistance. Each course of a broad-spectrum agent when a narrow-spectrum agent would suffice accelerates resistance pressure. Across the population of millions of UTI visits per year, the cumulative resistance contribution is enormous — and almost entirely avoidable if first-pass diagnostic accuracy were improved.

Dr. David Nash invoked the Triple Aim as the organizing framework for the policy argument: UTI reform simultaneously improves the health of the population (by reducing sepsis, hospitalization, and deaths attributable to treatment failure), improves the patient experience of care (by reducing the suffering, cycling, and abandonment that characterize recurrent UTI), and reduces cost by reducing waste (by eliminating the escalated care that follows first-line failure). Few clinical quality improvement opportunities map so directly and powerfully to all three aims.

The policy implication is that UTI management is ready for the same outcome-measurement infrastructure that has been built around hypertension, diabetes, and cardiovascular disease management — a dashboard of performance metrics, publicly reported, with reimbursement linked to outcomes rather than to volume of encounters. Dr. Nash was direct: the measures exist, or can be developed; what is lacking is the will to make them standard.

A path forward — what responsible evolution looks like.

The roundtable was not convened to describe a crisis without also identifying a path forward. The panel's discussion of metrics, technology, and the five-year horizon converged on a set of practical recommendations that are actionable within current clinical and policy infrastructure.

The single highest-leverage intervention identified by the panel is the creation of a standard measurement framework for UTI management outcomes. Dr. David Nash offered a clear prescription: identify the measures, create a performance dashboard, make the data transparent to practitioners and then to consumers, and link payment to outcomes. The specific metrics the panel endorsed include: time to symptomatic improvement measured through patient-reported outcomes at two weeks post-treatment; rate of antibiotic courses per patient per year capturing antibiotic usage rates; rate of inappropriate antibiotic courses, capturing the scale of optimizable prescribing; recurrence rate at six months as a direct measure of first-pass resolution efficacy; rate of care escalation following initial UTI treatment; rate of antibiotic resistance emergence in organisms from recurrent UTI patients; and patient-reported outcomes on quality of life domains, including the validated instrument Kramer's team has developed.

Dr. Nash was unambiguous on the fundamental principle: we are only going to improve what we measure. The current state — in which the absence of a callback is treated as evidence of resolution — is not a measurement system. It is an absence of one.

The panel was broadly aligned on the direction of diagnostic evolution: toward faster, more sensitive, pathogen-specific testing with integrated evidence-based antibiotic effectiveness data that is returned within a clinically actionable timeframe. But the critical emphasis — the point the panel returned to repeatedly — is that the measuring stick for any new diagnostic must be the quality of direction it provides. A test should be evaluated not only by what it detects, but by how accurately it tells the clinician what to do in an evidence-based manner.

Dr. Frank Cockerill identified the historical parallel that makes the urgency of this moment clear: every major infectious disease category — meningitis, pneumonia, STIs, GI infections — has been transformed by the adoption of rapid molecular diagnostics. UTI is the last frontier. The process for adopting rapid, advanced UTI tests is the same process that succeeded for other infectious diseases - initial resistance, recognition of the need, generation of outcomes evidence, gradual acceptance, then rapid universal adoption. The need exists and outcomes evidence exists. Now we need to push for acceptance and urgency in universal adoption.

What is needed is a new category of diagnostic testing — one that can best be described as Total Infection Response Testing (TIRT). Rather than evaluating organisms in isolation, TIRT evaluates antibiotic effectiveness at the level of the complete, patient-specific infection, including polymicrobial interactions. Its value is measured precisely by the quality of direction it provides: not just what organisms are present, but which antibiotic will work against this patient's infection as it actually exists. This is the standard against which all UTI diagnostics should be evaluated — and by which current approaches, whether culture, conventional AST, or PCR alone, fall short.

David Nash's most pointed strategic observation was that the effort to improve UTI diagnostics has been overfocused on urologists and has paid insufficient attention to the clinicians who see the majority of UTI patients: primary care physicians, OBGYNs, and internists. The same observation applies to patient advocates: organizations like Live UTI Free and Let's Talk UTI, which collectively reach millions of patients annually, are natural amplifiers of a credible Why Change message.

The practical implication is that the path to changing UTI management at scale runs through primary care — the setting in which most UTIs are first encountered — and through the patient community, which has documented demand and unmet need that the healthcare system has not yet served.

Dr. Nash's prescription for the near term was specific: collect outcome data in capitated, bundled payment, and value-based care settings, and use those pilots to demonstrate that first-pass diagnostic accuracy reduces downstream spending. This is the evidence that will move CFOs and health system administrators — not the clinical argument alone, but the clinical argument expressed as a reduction in escalated care costs, ED visits, and hospitalizations attributable to UTI treatment failure.

The panel was in agreement that this evidence needs to be generated quickly — not three years from now. The convergence of AI-assisted clinical decision support, mobile diagnostic platforms, and a growing evidence base for advanced UTI testing creates a window of opportunity that previous generations of UTI improvement efforts did not have.

Conclusions.

The UTI crisis is not a crisis of ignorance. It is a crisis of inertia.

The clinical, economic, and patient burden of current UTI management is documented, quantifiable, and in the most important respects, avoidable. The diagnostic tools that would enable better outcomes exist. The evidence supporting their use is accumulating. What has been missing is the coherent, multi-stakeholder articulation of why change is necessary and what it would look like.

This roundtable was convened to begin filling that gap. The panel's five voices — spanning health policy, laboratory medicine, urology, patient advocacy, and research — arrived at a common conclusion expressed in different registers: the current approach to UTI is a solvable systemic failure hiding in plain sight, and the time to address it is now.

The Why Change framework presented in this document is not a commercial argument. It is a clinical, economic, and ethical argument grounded in data, validated by diverse expert perspectives, and directed at anyone who manages UTI patients, pays for UTI care, advocates for UTI patients, or sets the policies and guidelines that govern UTI management.

Five commitments for the field.

1. Focus on getting the right direction the first time. The wrong antibiotic is the catalyst for every downstream harm. Diagnostic tools must be evaluated by the accuracy of the treatment direction they provide, not only by the organisms they detect.
2. Measure what matters. Establish patient-reported outcomes, recurrence rates, and antibiotic appropriateness as standard metrics. We improve only what we measure.
3. Rethink what is front-line. The tools designed in the 1950s for a narrow obstetric population cannot carry the diagnostic burden of modern UTI management. For high-risk populations (e.g., the elderly), the evidence for first line use of more advanced approaches is sufficient to act now.
4. Expand the conversation. UTI is primarily a primary care problem. The path to population-level improvement runs through family medicine, internal medicine, infectious disease, OBGYN, and shared decision-making with the patient population — not only through urologists.
5. Follow the patient. Patients who have experienced repeated failure are a resource, not a nuisance. Their experience is the most honest indicator of how the system is performing. Incorporate it.

UTI is the last frontier of infectious disease diagnostics. It is also, in the panel's collective view, the most tractable. The solutions are available. The measurement frameworks can be built. The patient demand is documented and substantial. What remains is the will to treat a common infection as the significant healthcare burden it is — and to build the clinical and diagnostic infrastructure that patients and providers deserve.

The following references represent a subset of the peer-reviewed literature underlying the statistical claims and evidence presented in this white paper. A full bibliography, including all 30+ peer-reviewed Pathnostics-associated publications, is available at pathnostics.com/references.